Mitral Stenosis

Dr Annette Vegas FRCPC, FASE Professor Anesthesiology



Toronto General Hospital Department of Anesthesia Perioperative Interactive Education

http://pie.med.utoronto.ca/TEE/



Outline

- Etiology
- Physiology
- Echocardiography
 - Valve
 - Secondary
- Assessment



http://pie.med.utoronto.ca/TEE/TEE_content/TEE_assessment_cardiacValves.html





Etiology

- Rheumatic (75%)
- Calcific
- Congenital
 - Parachute MV
 - Shone complex
- Inflammatory
 - Lupus
 - Rheumatoid arthritis
- Mass









Rheumatic MV





- Leaflet thickening + calcification
- Commissural fusion
- Chordal shortening + fusion = funnel shape





Calcific MV Pathology





- Annular calcification
 - Posterior leaflet
- Leaflet base rather then tip
- No commissural fusion
- Directly involves AV





Physiology MS

- Diastole
- LV relaxes, LVP < LAP, MV opens



Normal: rapid =







Rheumatic MV 2D TEE



- Thickened leaflet (>3mm)
- Restricted motion
 - At tips
 - Diastolic doming (hockey stick)
- Commissural fusion





Rheumatic MV 2D TEE



- Chordae
 - Thick
 - Short
- Restricted leaflet motion





Rheumatic MV 3D TEE







Calcific MV 2D TEE



- Restricted motion
 - At base
 - No diastolic doming
- No Commissural fusion





Calcific MV 3D TEE







Calcified Rheumatic



MS Secondary Changes

- Left Atrium
 - Enlarged
 - Spontaneous echo contrast (SEC)
 - Thrombus
- MV (MR)
- Pulmonary hypertension
 - RV dilatation
 - RVSP





Secondary Changes LA



PIE



51 bpm

Secondary Changes MR







Secondary Changes PAP



- IAS shift to R
- RV dilatation
- TR \bigcirc
 - Estimate RVSP

↑ PAP

- Not measure of MS severity 0
- Does reduce survival 0





Vel 387 cm/s PG 60 mmHa

-50.(cm/s - 5.0

-4.0 -3.0

-2.0 -1.0 m/s

Secondary Changes



MS Assessment







Severity MS

| | Mild | Moderate | Severe |
|--|-------|----------|--------|
| MVA* (cm ²) | > 1.5 | 1 – 1.5 | < 1 |
| Mean PG** (mmHg) | < 5 | 5 - 10 | > 10 |
| PAP** (mmHg) | < 30 | 30 - 50 | > 50 |
| *specific, **supportive Only f HR 60-80 NSR | | | |
| No single value defines severity | | | |





MS Color Doppler



- Diastolic flow
- Turbulent antegrade
 - Nyquist 50-60cm/s
- Flow acceleration in LA





MS Spectral Doppler



PG between LA \rightarrow LV determines rate of pressure equalization in diastole



record with CWD

MS Spectral Doppler

- High E wave velocity
- Flattened E wave slope
- Fusion E and A wave
- PG: mean, peak
- MVA: PHT, DT



MR

- Higher E velocity
- Peak PG > 20mmHg
- Mean PG < 10mmHg





MS Spectral Doppler







MS PG Limitations







MVA

| Anatomic | | | |
|---------------------|--|--|--|
| Planimetry | 2D TG Basal SAX, 3D | | |
| Functional | | | |
| Pressure Half Time | 220 ÷ PHT (ms) | | |
| Deceleration Time | 759 ÷ deceleration time (ms) | | |
| Continuity Equation | <u>π r² x VTI_{LVOT}</u> VTI _{mitral} | | |
| PISA | 2πr ² x <u>Valiasing</u> x α /180 Peak Vmitral | | |





MVA Limitations

| MVA | Avoid in | Use in |
|------------------------|--|---------------------------|
| Planimetry | Heavily calcified | |
| PHT | AI, LV dysfunction, ASD, diastolic dysfunction | MR, AF |
| Continuity Equation | AI, LVOT obstruct, MR, AF, intracardiac shunt | Calcific MS |
| PISA | | AI, MR, prosthetic, AF |





MS with Multivalve Lesions

| Lesion | PG | MVA |
|--------|---------------------------|--|
| MR | High peak PG, use mean | Underestimate MVA by continuity and PHT |
| AI | Low flow/PG | Overestimate MVA Continuity (↑ AV flow) ↓ PHT (from ↑ LVEDP) |
| AS | Low flow/ PG | • Overestimate MVA, prolong PHT from impaired LV relax |
| TR | | Gorlin formula invalid |





MS MV Area Planimetry

- Anatomic measure
- Trace open MV orifice in mid-diastole
- Identify leaflet tips
- Repeat measures in AF
- Unreliable in calcific MS due to shadowing
- Underestimate 个HR







MS MVA Pressure Half-Time

- Time (in ms) from peak
 MV to half initial value
- MVA = 220/PHT
 - X Normal
 - × Post BMV
 - X Post Prosthetic
- If bimodal use mid part
- Deceleration time
 - Time from peak to 0
 - PHT = 0.29DT
 - MVA = 759/DT







Velocity

MS MVA PHT Limitations

Velocity



(Overestimate MVA)





Long PHT (Underestimate MVA)

• \uparrow LVEDP/ \downarrow compliance

- Al
- Cardiomyopathy/LVH
- Diastolic dysfxn (aging)
- \downarrow LAP compliance
 - ASD
 - MR
 - AF, \uparrow HR

Large LA

Abnormal relaxation

Avoid PHT in

- Elderly
- Calcific
- Diastolic dysfunction
- ? Post CPB, BMV





MVA PHT



MV mean PG 5mmHg, MVA 1.11cm²





MS MVA Continuity



Continuity Equation



Avoid if

- AI (overestimate),
- MR (underestimate)
- ASD
- AF





MVA Continuity







MVA PISA







MVA PISA







MVA PISA







MV Interventions in MS

| Class | 2014 AHA/ACC Guidelines MV Interventions in MS | Level of Evidence |
|-------|--|----------------------|
| I | PBC for symptomatic patients, severe MS (MVA ≤1.5 cm2, stage D) and favorable valve morphology without LA thrombus or moderate-to-severe MR | A |
| | MV surgery (repair, commissurotomy, or valve replacement) for severely symptomatic patients (NYHA class III to IV), severe MS (MVA ≤1.5 cm2, stage D), not high risk for surgery or not candidates or failed PBC | В |
| | Concomitant MV surgery for severe MS (MVA ≤1.5 cm2, stage C or D) undergoing other cardiac surgery | C |
| lla | PBC reasonable asymptomatic very severe MS (MVA ≤1.0 cm2, stage C) and favorable valve morphology without LA thrombus or moderate-to-severe MR | C |
| | MV surgery reasonable severely symptomatic (NYHA class III to IV), severe MS (MVA ≤1.5 cm2, stage D), with other operative indications | С |
| IIb | PBC consider asymptomatic, severe MS (MVA ≤1.5 cm2, stage C) favorable valve morphology without LA thrombus or moderate-to-severe MR with new onset of AF | С |
| | PBC consider symptomatic MVA > 1.5 cm2 with hemodynamically significant MS based on PCWP > 25 mm Hg or mean MV gradient > 15 mm Hg during exercise. | С |
| | PBC consider severely symptomatic (NYHA class III to IV), severe MS (MVA ≤1.5 cm2, stage D), suboptimal valve anatomy and not candidates/high risk for surgery | С |
| | Concomitant MV surgery consider moderate MS (MVA 1.6 – 2.0 cm2) undergoing other cardiac surgery | С |
| | MV surgery + LAA excision consider for severe MS (MVA ≤1.5 cm2, stages C and D) with recurrent embolic events despite adequate anticoagulation. | С |





MS Management Wilkins Score

Based on valve morphology

| Grade | Mobility | Thickening | Calcification | Subvalvular Thickening |
|-------|---|---|--|---|
| 1 | Highly mobile valve with only leaflet tips restricted | Leaflets near normal in thickness (4–5 mm) | A single area of increased echo brightness | Minimal thickening just below the mitral leaflets |
| 2 | Leaflet mid and base portions have normal mobility | Midleaflets normal, considerable thickening of margins (5–8 mm) | Scattered areas of brightness confined to leaflet margins | Thickening of chordal structures extending to one-third of the chordal length |
| 3 | Valve continues to move forward in diastole, mainly from the base | Thickening extending through the entire leaflet (5-8 mm) | Brightness extending into the mid-portions of the leaflets | Thickening extended to distal third of the chords |
| 4 | No or minimal forward movement of the leaflets in diastole | Considerable thickening of all leaflet tissue (>8- 10 mm) | Extensive brightness throughout much of the leaflet tissue | Extensive thickening and shortening of all chordal structures extending down to the papillary muscles |

The total score is the sum of the four items and ranges between 4 and 16.

Low score \leq 8, good outcome



Wilkins, GT, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. *Br Heart J, 1988 60*(4), 299-308.



MS Management Cormier Score

Based on leaflet calcification and subvalvular

| Echocardiographic group | Mitral valve anatomy |
|----------------------------|---|
| Group 1 | Pliable non-calcified anterior mitral leaflet and mild subvalvular disease (i.e. thin chordae ≥10 mm long) |
| Group 2 | Pliable non-calcified anterior mitral leaflet and severe subvalvular disease (i.e. thickened chordae <10 mm long) |
| Group 3 | Calcification of mitral valve of any extent, as assessed by fluoroscopy, whatever the state of subvalvular apparatus |



lung, B, Cormier, B, et al. (1996). Immediate results of percutaneous mitral commissurotomy. A predictive model on a series of 1514 patients. *Circulation 1996, 94*(9), 2124-2130.



MS Management 3D TEE Score

Divides leaflets into 3 portions, scores each

| | Leaflet | s | | | | |
|---|------------------------------------|----------|--------|-------------------|--------|-------|
| | Anterior leaflet | | | Posterior leaflet | | |
| | A1 | A2 | A3 | P1 | P2 | P3 |
| ^a Thickness (0–6) | 0-1 | 0-1 | 0-1 | 0-1 | 0-1 | 0-1 |
| ^a Mobility (0–6) | 0-1 | 0-1 | 0-1 | 0-1 | 0-1 | 0-1 |
| ^b Calcification (0-10) (0=no, 1-2=calcified) | 0–2 | 0-1 | 0–2 | 0–2 | 0-1 | 0–2 |
| | ^b Subvalvular apparatus | | | | | |
| | Proxim | al third | Middle | e third | Distal | third |
| Thickness (0-3) (0=normal, 1=thickened) | 0-1 | | 0-1 | | 0-1 | |
| Separation (0-6) (0=normal, 1=partial, 2=no) | 0–2 | | 0–2 | | 0–2 | |

^aNormal=0, mild=1-2, moderate=3-4, severe >5
^bNormal=0, mild=1-2, moderate=3-5, severe >6

| Mild | Moderate | Severe |
|------|----------|--------|
| <8 | 8 - 13 | ≥14 |



Soliman O I, et al. New Scores for the Assessment of Mitral Stenosis Using Real-Time Three-Dimensional Echocardiography. *Curr Cardiovasc Imaging Rep 2011, 4*(5), 370-377.



Selected Readings

- Cherry AD, Maxwell CD, Nicoara A. Intraoperative Evaluation of Mitral Stenosis by Transesophageal Echocardiography. Anesth Analg 2016;123:14-20.
- Baumgartner H, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1-23.
- Wunderlich NC, Beigel R, Siegel RJ. Management of Mitral Stenosis Using 2D and 3D Echo-Doppler Imaging. JACC: Cardiovasc Imaging 2013;6:1191-1205.
- Alaa Mabrouk SO, Tanaka H, et al. Comparison of mitral valve area by pressure half-time and proximal isovelocity surface area method in patients with mitral stenosis: effect of net atrioventricular compliance. Eur J Echocardiogr 2011;12:283–290.
- Wilkins, GT, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. *Br Heart J, 1988 60*(4), 299-308.
- Iung, B, Cormier, B, et al. (1996). Immediate results of percutaneous mitral commissurotomy. A predictive model on a series of 1514 patients. *Circulation 1996, 94*(9), 2124-2130.
- Soliman O I, et al. New Scores for the Assessment of Mitral Stenosis Using Real-Time Three-Dimensional Echocardiography. *Curr Cardiovasc Imaging Rep 2011,* 4(5), 370-377.





Which of the following is not a finding in rheumatic MS ?

- **1**. Commissural fusion
- 2. Annular + leaflet base calcification
- 3. Chordal shortening + fusion
- 4. Leaflet tip calcification
- 5. Diastolic doming





What is the calculated MVA ?

- **1.** 0.72
- 2. 0.92
- **3**. 1.08
- **4.** 1.20
- **5**. 1.40







Which of the following is true?

- A. Mean gradient is underestimated with tachycardia
- B. MR underestimates MS severity by mean PG
- C. Pressure half time is decreased with reduced cardiac output
- D. Al overestimates MVA by PHT method





Severe MV stenosis is diagnosed when the normal MVA is reduced by at least ?

- **1**. 25%
- 2. 33%
- **3**. 50%
- **4.** 66%
- **5.** 75%





Which secondary finding is not consistent with the isolated MS ?

- 1. Dilated left atrium
- 2. Dilated right ventricle
- 3. Dilated left ventricle
- 4. Dilated tricuspid valve annulus





What is the calculated MVA (in cm²) based on the information provided:

r 1.7cm, Valias 25cm/s, Vmax 250cm/s, α angle 100

0.8
 1.0
 1.0
 1.2

4. 1.4

MVA = $2\pi r^2 x Va/Vmax x \alpha/180$ = 2(3.14) (1.7)² x (25/250) x 100/180 = 1.0



